Evolution of national and European policies in the field of rare diseases and their impact over the past five years
نویسندگان
چکیده
The 2009 Council Recommendation on an Action in the Field of Rare Diseases (2009/C 151/02) [1] encouraged Member States to elaborate a national plan or strategy for rare diseases before the end of 2013. One of the principal tasks of the European Union Committee of Experts on Rare Diseases (EUCERD) [2], through its Scientific Secretariat, was to analyse the results of the actions cited in the Recommendation, notably through the production of the annual report on the ‘State of the Art of Rare Disease Activities in Europe’ [3]. The 2014 edition of the report considers the impact of European policy and national plans/strategies (Figure 1) on the organisation of health care and services for patients with rare diseases, including access to diagnosis and treatment, as well as considering progress in the field of registries, rare disease research initiatives, the genetic testing offer, access to information on rare diseases, patient organisations, and specialised social services. In terms of national plans and strategies for rare diseases, by end 2013, the deadline to elaborate national plans/ strategies for rare diseases fixed by the Council Recommendation, most EU Member States had submitted
منابع مشابه
Elucidation of Current Status, Implemented Policies and Interventions, Achieved Results, and Future Plans of Iran to Control the Risk Factors of Non-Communicable Diseases: A Review Article
Background: This review study aims to shade light on the effects of carrying out interventions and policies in order to reduce the incidence and prevalence of non-communicable diseases (NCDs) and their behavioral risk factors (i.e., unhealthy diet, insufficient physical activity and smoking) and strategies and approaches to reduce their attributed burden. Method: In this research, the documen...
متن کاملBiopharmaceutical Innovation System in China: System Evolution and Policy Transitions (Pre-1990s-2010s)
Background: This article sets up the initial discussion of the evolution of biopharmaceutical innovation in China through the perspective of sectoral innovation system (SIS).Methods: Two data sources including archival documentary data and field interviews were used in this study. Archival documentary data was collected from China Food and Drug Administration (CFDA) and Chinese National Knowled...
متن کاملSunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
Relationships between health professionals and pharmaceutical manufacturers can unduly influence clinical practice. These relationships are the focus of global transparency efforts, including in Europe. We conducted a descriptive content analysis of the transparency provisions implemented by February 2017 in nine European Union (EU) countries concerning payments to health professionals, with du...
متن کاملThe Impact of Geographical Factors on the Prevalence of Pervasive Diseases in Guilan, Qajar Era in Perspective of European Tourists
European tourists in their reports from Guilan in the Qajar era, also have addressed the issue of health and deadly diseases affecting lives of people, such as rice fever, malaria, cholera, and plague in addition to pointing out the numerous social tragedies. From these tourists’s point of view, the weather conditions, geographical location, livelihood and some living and social habits and beha...
متن کاملAn Overview of the Epigenetic Modifications of Gene Expression in Tumorigenesis
The five leading causes of cancer-related deaths are lung (1,760,000 deaths), colorectal (862,000 deaths), stomach (783,000 deaths), liver (782,000 deaths), and breast (627,000 deaths) cancers. Epigenetic changes can alter chromatin compaction, leading to the regulation of geneexpression without changing the primary DNA sequence.Epigenetic mechanisms are normally involved incellular processes s...
متن کامل